3/6/2013

The 2.3% medical device tax could cost jobs and stymie the development of new products, Rep. Charles Boustany, R-La., said in testimony before the House Ways and Means Committee. In later comments to reporters, he said that efforts to repeal the levy may be considered "in the context of fundamental tax reform," echoing comments previously made by the medtech industry.

Related Summaries